Analysis Metabolite Name Measured Value Units Cell Type Stimulation
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-1684091Peak areaPAK TNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-1852583Peak areaPAK Untreated
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2082558Peak areaPAK IFN-G
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2088098Peak areaBS4 Untreated
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2114738Peak areaPAK TNF-alpha
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2160955Peak areaBS4 TNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2213163Peak areaPAK IL-17A
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2365396Peak areaBS4 TNF-alpha
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2383618Peak areaBS4 IL-17A
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2421187Peak areaHAHA IFN-G
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2479594Peak areaHAHA TNF-alpha
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2497470Peak areaBS4 IFN-G
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2729790Peak areaHAHA TNF-alpha+IL-17A
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-2875890Peak areaHAHA IL-17A
Reversed phase NEGATIVE ION MODELEUCINE (CAS# 328-39-2); (M-H)-3464109Peak areaHAHA Untreated
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+12900000Peak areaHAHA TNF-alpha
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+13100000Peak areaPAK TNF-alpha
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+13300000Peak areaPAK Untreated
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+13400000Peak areaHAHA IL-17A
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+13500000Peak areaHAHA IFN-G
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+13900000Peak areaHAHA TNF-alpha+IL-17A
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+14200000Peak areaHAHA Untreated
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+14300000Peak areaPAK IL-17A
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+14400000Peak areaPAK TNF-alpha+IL-17A
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+14500000Peak areaBS4 IL-17A
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+14700000Peak areaBS4 Untreated
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+14900000Peak areaPAK IFN-G
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+15900000Peak areaBS4 TNF-alpha
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+16500000Peak areaBS4 TNF-alpha+IL-17A
Reversed phase POSITIVE ION MODELEUCINE (CAS# 328-39-2); (M+H)+16700000Peak areaBS4 IFN-G

Return to search page
  logo